Melissa A Stockton1, Michael Udedi2,3, Kazione Kulisewa3, Mina C Hosseinipour4,5, Bradley N Gaynes5, Steven M Mphonda4, Joanna Maselko1, Audrey E Pettifor1, Ruth Verhey6, Dixon Chibanda6, Ilana Lapidos-Salaiz7, Brian W Pence1. 1. Epidemiology Department, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, United States of America. 2. NCDs & Mental Health Unit, Ministry of Health, Lilongwe, Malawi. 3. Department of Mental Health, University of Malawi, College of Medicine, Blantyre, Malawi. 4. University of North Carolina Project-Malawi, Tidziwe Centre, Lilongwe, Malawi. 5. Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States of America. 6. Friendship Bench Zimbabwe, Milton Park, Harare, Zimbabwe. 7. United States Agency for International Development (USAID), Arlington, VA, United States of America.
Abstract
BACKGROUND: Depression is highly prevalent among patients newly starting antiretroviral treatment (ART) in Malawi and many other countries. Untreated depression at ART initiation can disrupt the HIV care continuum. Effective approaches for depression screening and treatment exist for low-resource settings, but they are rarely applied. Identifying effective implementation strategies are critical. METHODS: A pilot program integrated depression screening and treatment into routine HIV care using existing staff at two public health clinics in Malawi in two phases; a screening-only "control" phase and an active "intervention" phase. During the intervention phase, providers prescribed antidepressants or referred patients for Friendship Bench problem-solving therapy. We evaluated the program's impact on retention in HIV care, viral suppression, and depression remission at 6 months using tabular comparisons and log-binomial models to estimate adjusted risk ratios and mean differences among the intervention group relative to the control group. RESULTS:Nearly all consenting participants were screened for depression appropriately and 25% had mild to severe depressive symptoms. During the intervention phase, 86% of participants with mild depressive symptoms started Friendship Bench therapy and 96% of participants with moderate to severe depressive symptoms started antidepressants. Few participants in the intervention group received consistent depression treatment over their first 6 months in care. In the adjusted main analysis, program exposure did not demonstrably affect most HIV or mental health outcomes, though the probability of currently being on ART at 6 months was significantly lower among the intervention group than the control group [RR 0.6(95%CI: 0.4-0.9)]. CONCLUSIONS: While it is feasible to integrate depression screening and treatment initiation into ART initiation, providing ongoing depression treatment over time is challenging. Similar implementation science studies focused on maintaining depression management will be increasingly important as we strive to understand and test the best ways to implement evidence-based depression treatment within HIV care.
RCT Entities:
BACKGROUND:Depression is highly prevalent among patients newly starting antiretroviral treatment (ART) in Malawi and many other countries. Untreated depression at ART initiation can disrupt the HIV care continuum. Effective approaches for depression screening and treatment exist for low-resource settings, but they are rarely applied. Identifying effective implementation strategies are critical. METHODS: A pilot program integrated depression screening and treatment into routine HIV care using existing staff at two public health clinics in Malawi in two phases; a screening-only "control" phase and an active "intervention" phase. During the intervention phase, providers prescribed antidepressants or referred patients for Friendship Bench problem-solving therapy. We evaluated the program's impact on retention in HIV care, viral suppression, and depression remission at 6 months using tabular comparisons and log-binomial models to estimate adjusted risk ratios and mean differences among the intervention group relative to the control group. RESULTS: Nearly all consenting participants were screened for depression appropriately and 25% had mild to severe depressive symptoms. During the intervention phase, 86% of participants with mild depressive symptoms started Friendship Bench therapy and 96% of participants with moderate to severe depressive symptoms started antidepressants. Few participants in the intervention group received consistent depression treatment over their first 6 months in care. In the adjusted main analysis, program exposure did not demonstrably affect most HIV or mental health outcomes, though the probability of currently being on ART at 6 months was significantly lower among the intervention group than the control group [RR 0.6(95%CI: 0.4-0.9)]. CONCLUSIONS: While it is feasible to integrate depression screening and treatment initiation into ART initiation, providing ongoing depression treatment over time is challenging. Similar implementation science studies focused on maintaining depression management will be increasingly important as we strive to understand and test the best ways to implement evidence-based depression treatment within HIV care.
Authors: Etheldreda Nakimuli-Mpungu; Colin M Smith; Kizito Wamala; James Okello; Josephine Birungi; Micheal Etukoit; Ramin Mojtabai; Jean B Nachega; Ofir Harari; Seggane Musisi; Edward J Mills Journal: Psychosom Med Date: 2022-09-06 Impact factor: 3.864
Authors: Daniel M Camp; Shamia J Moore; Drew Wood-Palmer; Kamini Doraivelu; Nancy M Holbrook; Rosalind N Byrd; Ameeta S Kalokhe; Mohammed K Ali; Eugene W Farber; Sophia A Hussen Journal: AIDS Patient Care STDS Date: 2022-08-26 Impact factor: 5.944
Authors: Bradley N Gaynes; Christopher F Akiba; Mina C Hosseinipour; Kazione Kulisewa; Alemayehu Amberbir; Michael Udedi; Chifundo C Zimba; Jones K Masiye; Mia Crampin; Ishmael Amarreh; Brian W Pence Journal: Psychiatr Serv Date: 2020-12-09 Impact factor: 4.157
Authors: Caroline A Bulstra; Jan A C Hontelez; Moritz Otto; Anna Stepanova; Erik Lamontagne; Anna Yakusik; Wafaa M El-Sadr; Tsitsi Apollo; Miriam Rabkin; Rifat Atun; Till Bärnighausen Journal: PLoS Med Date: 2021-11-09 Impact factor: 11.069
Authors: Melissa A Stockton; Caroline E Minnick; Kazione Kulisewa; Steven M Mphonda; Mina C Hosseinipour; Bradley N Gaynes; Joanna Maselko; Audrey E Pettifor; Vivian Go; Michael Udedi; Brian W Pence Journal: Glob Health Sci Pract Date: 2021-09-30
Authors: Ha V Tran; Ha T T Nong; Thuy T T Tran; Teresa R Filipowicz; Kelsey R Landrum; Brian W Pence; Giang M Le; Minh X Nguyen; Dixon Chibanda; Ruth Verhey; Vivian F Go; Hien T Ho; Bradley N Gaynes Journal: JMIR Form Res Date: 2022-07-08
Authors: Lucy Cunnama; Elaine J Abrams; Landon Myer; Tamsin K Phillips; Caitlin M Dugdale; Andrea L Ciaranello; Allison Zerbe; Victoria Iyun; Kim MacQuilkan; Vanessa Daries; Edina Sinanovic Journal: Trop Med Int Health Date: 2020-10-02 Impact factor: 2.622